Joshua Yang

Hi, I'm Josh, the co-founder and CEO of Glyphic Biotechnologies, a VC-funded biotechnology startup commercializing a next-generation protein sequencing platform. My first startup Nephrosant has raised over $22M in funding to commercialize a low-cost, non-invasive diagnostic assay for kidney injury.

I graduated Phi Beta Kappa, Tau Beta Pi, and Summa Cum Laude from the University of California, San Diego, which I attended fully-funded on the Jacobs School Scholarship. I double majored in Bioengineering: Biotechnology B.S. and General Biology B.S where I was a Barry Goldwater Scholar and the Valedictorian in the Department of Bioengineering. Subsequently, I completed a Master of Translational Medicine degree through the University of California, San Francisco and University of California, Berkeley in the Department of Bioengineering, from where I spin-out my first startup. I am currently on leave of absence from the MSTP MD-PhD at the Johns Hopkins University School of Medicine and Department of Biomedical Engineering. I subsequently graduated with an MBA from the Stanford University Graduate School of Business, where I was the Henry Ford II Scholar (Valedictorian), a Siebel Scholar, and an Arjay Miller Scholar.

My first-author, peer-reviewed publications have been published in top-tier journals such as Nature Reviews Genetics and Science Translational Medicine. I am also an inventor on 6 issued/filed patents and author on 18 research articles. I was named to the Forbes 30 Under 30 Healthcare list in 2021.

In my free time, I enjoy going to farmer's markets on Sunday mornings, sipping on dirty chai lattes, and creating pastries from scratch.

Joshua Yang is the Co-Founder and CEO at Glyphic Biotechnologies, based in United States, North America. With a background in Biotechnology, Joshua Yang has a rich history of leadership and innovation.Joshua Yang studied MD Medicine at Johns Hopkins University School of Medicine. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.